home / stock / cytr / cytr news

CYTR News and Press, CytRx Corporation From 08/13/20

Stock Information
Company Name: CytRx Corporation
Stock Symbol: CYTR
Market: NASDAQ
Website: cytrx.com
Menu
CYTR CYTR Quote CYTR Short CYTR News CYTR Articles CYTR Message Board
Get CYTR Alerts

News, Short Squeeze, Breakout and More Instantly...
CYTR - CytRx's Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign

Exposes Dissident as a “Frivolous Litigant” with a Highly-Questionable Background and Documented History of Poor Judgement Highlights Dissident’s Efforts to Smear CytRx and Misrepresent his Qualifications, Including by Withholding Information from Stockholders R...
CYTR - CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders

LOS ANGELES , Aug. 10, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has mailed a letter to stockholders in connection wit...

CYTR - Arimoclomol application in U.S. fails to lift CytoRx

Thinly traded nano cap CytRx ( OTCQB:CYTR   -1.3% ) is down out the gate this morning on the heels of its announcement that Orphazyme A/S has completed its rolling U.S. marketing application seeking approval of arimoclomol for the treatment of Niemann-Pick disease type-C , a rare inh...

CYTR - CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C

LOS ANGELES , July 21, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have completed their rolling submissio...
CYTR - CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with The Michael J. Fox Foundation on Parkinson's Disease Research

LOS ANGELES , July 20, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphazyme A/S announced it will join The Michael J. Fox Fo...

CYTR - CytRx up ~4% as Orphazyme reports positive outcome from mid-stage study of Arimoclomol in Gaucher Disease

CytRx ( OTCQB:CYTR +4.3% ) highlights that Orphayzme announces topline results of Phase 2 dose-finding study with arimoclomol in Gaucher disease (buildup of certain fatty substances in certain organs); In 2011, CytRx sold the rights to arimoclomol to Orphazyme. More ne...

CYTR - CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease

LOS ANGELES , June 29, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced topline results of their Phase 2 dose-...
CYTR - CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C

LOS ANGELES , June 1, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have initiated the submission of t...

CYTR - CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

LOS ANGELES , May 26, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have received Fast Track Designation...

CYTR - CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin

LOS ANGELES , May 21, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2...
Previous 10 Next 10